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Background: Gestational diabetes mellitus (GDM) reﬂects an increased risk of developing type 2 diabetes (T2D)
after pregnancy in women. Offspring born to mothers with GDM are at an elevated risk of obesity and T2D at a
young age. Currently, there are lack of ways for identifying women in early pregnancy who are at risk of devel-
oping GDM. As a result, both mothers and fetus are not treated until late in the second trimester when GDM is
diagnosed. The recent advance in metabolomics, a new approach of systematic investigation of the metabolites,
provides an opportunity for early detection of GDM, and classifying the risk of subsequent chronic diseases
among women and their offspring.
Methods:We reviewed the literatures published in the past 20 years on studies using high-throughput metabo-
lomics technologies to investigate women with GDM and their offspring.
Conclusions:Despite the inconsistent results, previous studies have identiﬁedbiomarkers that involved in speciﬁc
metabolite groups and several pathways, including amino acid metabolism, steroid hormone biosynthesis,
glycerophospholipid metabolism, and fatty acid metabolism. However, most studies have small sample sizes.
Further research is warranted to determine if metabolomics will result in new indicators for the diagnosis,
management, and prognosis of GDM and related complications.
© 2018 Elsevier Inc. All rights reserved.1. Introduction
Gestational diabetes mellitus (GDM), one of most common preg-
nancy complications, is deﬁned as any degree of glucose intolerance
with onset or ﬁrst recognition during pregnancy.1 The prevalence of
GDM varies worldwide, ranging from 1 to 14% of all pregnancies
depending on diagnostic criteria and study population.2 Recent
data have shown a signiﬁcant increase in the prevalence of GDM
among women of various ethnic/racial backgrounds and in different
geographic regions.3–7 The increase in prevalence of GDM is likely to
continue as a rise in obesity rates for girls and women of reproductive
age has been observed globally.
1.1. Diagnosis of GDM
The diagnosis of GDM relies on detecting elevated plasma glucose,
often in the late of the second trimester; however, there currently is nowork.
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g/10.1016/j.jdiacomp.2018.01global consensus on the diagnostic criteria. In 2010, The International
Association of Diabetes and Pregnancy Study Groups (IADPSG) recom-
mended a “one-step” approach, in which all pregnant women without
known diabetes (type 1 or 2) receive a 75 g 2-hour oral glucose tolerance
test (OGTT) between 24 and 28weeks gestation.8 In 2013, the National
Institutes of Health (NIH) expert panel recommended the “two-step”
approach, in which pregnant women who screen positive after a 50 g
1-hour OGTT, take a subsequent 100 g 3-hour OGTT between 24 and 28
weeks gestation.9 These approaches also differ onwhether two abnormal
values are required, and what diagnostic cut-off values should be used.
Given that there are data to support both approaches, in 2014 the
American Diabetes Association (ADA) recommended both options for
diagnosing GDM.1
1.2. Health consequences for women with GDM and their offspring
Although most women return to a normal glucose status after
delivery, 20% of women with GDM develop impaired fasting glucose
(IFG) and/or impaired glucose tolerance (IGT) during 6–12 weeks
postpartum.10,11 More importantly, women with GDM are at increased
risk of developing of type 2 diabetes (T2D) later in life. The increased
risk of T2D amongwomenwith GDM has been documented in different
populations and countries. On average, the risk of developing of T2D isn with gestational diabetes mellitus and their offspring: Review of
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GDM.10 A large retrospective cohort study in Australia demonstrated
the risk of developing diabetes increased with time from women's
index pregnancy: the cumulative incidence of diabetes was 2.6% at 2
years, 8.1% at 5 years, 17.3% at 10 years, and 25.8% at 15 years after diag-
nosis of GDM.12 Recent data have also indicated that independent of
T2D or obesity, women with GDM might be at an increased risk of
hypertension,13 metabolic disorders14 and even cardiovascular disease
(CVD) events.15 In addition, emerging evidence tends to suggest that
women with GDM represent a population who are more likely to de-
velop CVD at a relatively younger age.16
GDM also has profound impacts on the offspring's health, both
short- and long-term. Biologically, maternal glucose can cross the pla-
centa but maternal insulin cannot. In response to the increased glucose
load, the fetal pancreas increases insulin production, which in turn, pro-
motes fetal growth and adiposity development.17 There is a growing
body of data that supports a positive association between maternal hy-
perglycemia and children's risk of health problems, including obesity,
diabetes, insulin resistance, IGT, T2D, CVD risk factors,18–21 and
autism.22 The available evidence suggests the higher risk of obesity
and T2D in offspring of GDM mothers is likely due to the intrauterine
environment which is independent of shared socioeconomic, lifestyle
and genetic factors within families.23,24 However, the molecular path-
ways underlying such associations remain unclear.1.3. Metabolic features of GDM
GDM is a signiﬁcant risk factor for development of T2D and CVD in
women and offspring. Therefore, identifying women at high risk of
GDM and understanding the metabolic changes in the early life of
their offspring has important public health and clinical signiﬁcance.
During the past several decades, a number of risk factors for GDM
have been identiﬁed, including advanced maternal age, family history
of diabetes, pre-pregnancy obesity, and multiple pregnancies.25 How-
ever, the etiology and pathogenesis of GDM remains unclear.
Pregnancy is accompanied by numerous metabolic changes in
women, one of which is a substantial decrease in insulin sensitivity.
Pregnancy-induced insulin resistance progressively develops in the sec-
ond and third trimesters and is thought to be secondary to increases in
maternal adiposity, aswell as increases in placental and other hormones
(e.g. human placental lactogen, placental growth hormone, progester-
one, estradiol, leptin, cortisol, prolactin, human chorionic gonadotropin,
tumor necrosis factor-alpha (TNF-α), and other inﬂammatory
mediators).26–28 Pregnant women have an increased insulin secretion
compared to a non-gravid state.29 In some women their β-cell function
cannot compensate for the increased insulin requirements in late preg-
nancy, and as a result develop GDM or hyperglycemia.30 Why these
women have inadequate β-cell compensation is not well known. GDM
may be caused by a complex set of interactions between genetic and en-
vironmental factors, triggered by a series ofmetabolic challenges during
pregnancy (e.g. promoting adipose tissue accumulation inmiddle gesta-
tion and developing insulin resistance in late pregnancy).
Although the etiology and pathogenesis of GDM is not fully under-
stood, themajority of womenwith GDM appear to have β-cell dysfunc-
tion that occurs in the background of chronic insulin resistance. To date,
only a few potential biochemical mediators of chronic insulin resistance
associatedwith GDMhave been investigated. It is likely that there is not
a single pathway or etiology that contributes to the development of
GDM. In addition, GDM may inﬂuence fetal organ development and
growth through maternal-placental-fetal glucose/insulin physiology
and these may result in a downstream effect on the fetal brain and pe-
ripheral systems. This complexity presents a challenge for completely
understanding the spectrum of molecular mechanisms associated
with maternal diabetes and how they impact physiological and meta-
bolic changes in offspring. The examination of one or several targetedPlease cite this article as: Chen Q, et al. Metabolomic proﬁling of wome
metabolomics studies. (2018), https://doi.org/10.1016/j.jdiacomp.2018.01molecules utilizing traditional methods has failed to detect the relevant
underlying molecular changes.
1.4. Overview of metabolomic
Progress in this research may be facilitated by recent developments
in technologies for comprehensive metabolic analysis, known as
“metabolomics”.31 This approach allows for large-scale simultaneous
analysis of numerous metabolites, and detects subtle changes in the
metabolic network in human bio-ﬂuids or tissues. In addition, metabo-
lomics can provide certain advantages relative to other “omics” technol-
ogies (genomics, transcriptomics, or proteomics) because it measures
molecular phenotypes that are the net results of other ‘omics’, therefore
providing the most integrated proﬁle of biological status.
The use of metabolomics for better understanding the etiology and
pathogenesis of disease consists of two sequential steps. The ﬁrst step
is an experimental technology, based on liquid or gas chromatogra-
phy–mass spectrometry (MS), or proton (1H) nuclear magnetic reso-
nance (NMR) spectroscopy. MS provides higher sensitivity and the
opportunity of optimized targeted analysis, andNMRoffers an overview
ofmodemetabolites, structural information, and higher reproducibility.
Using these new technologies, metabolomics can investigate the com-
plete set ofmetabolites or low-molecular-weight intermediates (molec-
ular weight b 1000) in a given biological sample. The second step is to
performmultivariate data analysis to determine differences in the met-
abolic proﬁles of individuals with certain health conditions/diseases
versus healthy controls. In brief, metabolomics is a comprehensive
method for qualitative and semi-quantitative analyses of metabolites
in human bio-ﬂuids or tissues. It has been rapidly used in the early de-
tection of diseases, measuring biological responses to treatments/inter-
ventions, identifying the underlying pathways between risk factors and
diseases, and discovering novel biomarkers associated with certain
health stages/conditions.
1.5. Metabolomics in GDM
Metabolomics has been used to analyzemetabolic proﬁles and iden-
tify novel biomarkers associated with insulin resistance and T2D. The
metabolic groups have been reported included carbohydrate metabo-
lites (e.g. glucose and fructose), lipid metabolites (e.g. phospholipids,
sphingomyelins, and triglycerides), and amino acid metabolites
(branched-chain amino acids, aromatic amino acids, glycine, and
glutamine).32–35 The pathophysiological changes that occur in T2D
and GDM are similar and use of this new technologymay aid our under-
standing of the etiology and pathogenesis of GDM. Furthermore, meta-
bolomicsmay increase our ability to identify early predictors of GDM or
classify the risk of subsequent CVD among women and their offspring.
These innovations call for a thorough review of what has been reported
in this area of literature to inform future directions for research, summa-
rize what has been found, and elucidate any challenges in the ﬁeld.
2. Literature research
We searched PubMed from January 2007 to April 2017 for studies
using high-throughput metabolomic technologies (i.e. MS or NMR) to
investigate women with GDM and their offspring. Key-words used in-
cluded “diabetes,” “gestational,” “gestational diabetes,” “metabolome”,
“metabolomics,” “metabolic disease”, “metabolic syndrome”, “impaired
glucose”, “HOMA-IR”, “HOMA-beta”, “insulin resistance”, “overweight”,
“obesity”, “body mass index”, “BMI”, “body weight”, and “adiposity”
(see Appendix A). Additionally, hand searching of the references cited
in identiﬁed articles was performed. Two authors (QC & EF) indepen-
dently searched the literature, reviewed the studies, and extracted the
data. Then two senior author (LC and GH) double checked the literature
search and the information extracted from each included article.n with gestational diabetes mellitus and their offspring: Review of
.007
3Q. Chen et al. / Journal of Diabetes and Its Complications xxx (2018) xxx–xxxThe ﬁndings of the review are organized in the following manner:
1)metabolic proﬁle of mothers in early pregnancy (prior to the diagno-
ses of GDM) that predict GDM; 2) metabolic proﬁle of mothers with a
diagnosis of GDM compared to those without at the time of diagnosis;
3)metabolic proﬁle at the postpartumofmotherswhohad experienced
GDM compared to those who did not; 4) the changes in metabolic pro-
ﬁle over time ofwomenwith GDMas compared towomenwithout, and
5)metabolic proﬁle of offspring who born to mothers who experienced
GDM and those who did not.
2.1. Metabolomics to predict GDM (bio-specimens collected before the di-
agnosis of GDM)
The early identiﬁcation of women who are at risk of developing
GDM is important since early treatment/interventions can be intro-
duced to reduce the adverse impacts of hyperglycemia for bothmothers
and offspring. We identiﬁed 9 studies, all with nested case-control de-
sign, that compared the metabolic proﬁle (before the diagnosis of
GDM) of women who later developed GDM to women who did not.
Of them, blood samples (plasma/serum) were analyzed in ﬁve studies,
urine samples were analyzed in four studies, and amniotic ﬂuids were
analyzed in two studies (some studies analyzed two types of bio-
specimens). We provided a summary table (Table 1) of all studies that
included in this review.
For women who later developed GDM compared to those who did
not, 5 studies that analyzed blood samples (plasma/serum) reported sig-
niﬁcant increases of itaconic acid, cis-aconitate acid,36 anthranilic acid,
alanine, glutamate, allantoin, serine,37 total fatty acids, myristic acid,
palmitic acid, palmitoleic acid, eicosapentaenoic acids,38 ﬂavonoids
(sesaminol 2-O-triglucoside, and tricin 7-neohesperidoside)39; and
signiﬁcant decreases in creatinine,37 phospholipids (unsaturated), (2E)-
14-hydroxytetradec-2-enoic acid or its isomer, (2E,13R)-13-
hydroxytetradec-2-enoic acid, 2,15-dihydroxy-pentadecanoic acid (or
its isomers), (7R,8S,9Z,12Z,15Z)-7,8-dihydroxy-9,12,15-octadecatrienoic
acid,39 trimethylamine-N-oxide and betaine.40
Among the 4 studies that analyzed urine samples, a signiﬁcant in-
crease was reported for women with GDM compared to controls in
choline,40–42 N-methyl-nicotinamide,40,41 glucose, xylose,41 3-
hydroxyisovalerate, 2-hydroxyisobutyrate, N-methyl-2-pyridone-5-
carboxamide,40 and citrate43; and in one study a signiﬁcant decreases
of 4-hydroxyphenylacetate and hippuratewere reported.41 Two studies
measured amnioticﬂuid42,44 and both reported increases in glucose and
decreases in glutamate. One study has also identiﬁed decreases in gly-
cine, proline, serine, taurine, acetate, formate, creatinine, and
glycerophosphocholine.44
In summary, studies on the metabolic proﬁle of women in early
pregnancy to predict risk of GDM has yielded minimally consistent
ﬁndings; with studies reporting decreases in blood creatinine,
trimethylamine-N-oxide, and betaine37,40; and increases of urine N-
methyl-nicotinamide,40,41 and urine choline.40–42 Two studies also
found increases of amniotic ﬂuid glucose, and decreases of amniotic
ﬂuid glutamate.42,44
2.2. Metabolomics to distinguish proﬁles of women with GDM
(bio-specimens collected after or simultaneous to GDM diagnosis)
Identifying metabolic differences between women who are
diagnosedwithGDMcompared to thosewho are not during the third tri-
mester may lead to better understanding of the associated complica-
tions, as well as potential inﬂuences on the metabolic development of
fetus. We identiﬁed 12 studies that compared the metabolic proﬁle of
women with GDM to women without GDM simultaneous or after diag-
nosis in late pregnancy. These studiesweremostly case-control in design
with only 4 studies utilizing a nested case-control design.38,39,43,45
A summary of the ﬁndings and speciﬁc metabolic differences are
reported in Table 1.Please cite this article as: Chen Q, et al. Metabolomic proﬁling of wome
metabolomics studies. (2018), https://doi.org/10.1016/j.jdiacomp.2018.01Blood samples (plasma/serum)were analyzed in 9 studies comparing
metabolic proﬁles of women with GDM to controls. Increases and de-
creases of metabolites within the same structural and functional class
were reported for women with GDM. Most consistently, increases in
amino acids were reported in 5 studies,45–49 and increases in fatty
acids were reported in four studies.38,48–50 Additional metabolites that
were found to be signiﬁcantly increased in women with GDM were
prostanoic acid, sesaminol 2-O-triglucoside, tricin 7-neohesperidoside,
dihydro-12-oxo-15-phytoenoic acid,39 acetylcarnitines,48,49 bile
acids,51 ketones,47,48 creatinine, carbohydrate (primary glucose),47
and other lipids and organic acids. Decreases in phospholipids,
(2E)-14-hydroxytetradec-2-enoic acid (or its isomer), (2E,13R)-13-
hydroxytetradec-2-enoic acid, 2,15-dihydroxy-pentadecanoic acid (or
its isomers), (7R,8S,9Z,12Z,15Z)-7,8-dihydroxy-9,12,15-octadecatrienoic
acid, 11α,20,26-trihydroxyecdysone,39 glycerophospholipids,45,48,49
1,5-anhydroglucitol,47 and gluconic acids45,48 were also reported.
Similarly, decreases in amino acids,45,46,48,49 and decreases in fatty
acids were also reported.45,48,49
Of the 3 studies that analyzed urine samples, one found citrate as a
signiﬁcantly different biomarkers to distinguish women with GDM
from non-GDM women,43 while 2 studies reported increases in amino
acids,48,52 with 148 also reporting a decrease in carnitine.
The analysis of hair samples was conducted in 1 study53 and in-
creases in adipic acid were found.
In summary, themetabolic proﬁle ofwomenwithGDMcompared to
controls has been found to have signiﬁcant increases and decreases in
speciﬁc metabolites. Despite the differences reported in the aforemen-
tioned studies, there is little consistency in the speciﬁc metabolites
that were signiﬁcant, and often the direction of change is contrary
within a metabolic structural or functional class.
2.3. Metabolomic proﬁles after the pregnancy (bio-specimens collected in
postpartum or later)
Differences in themetabolomic proﬁle after the pregnancy are likely
associated with the long-term complications of GDM and could be used
as screening tools for predicting the risk of future complications. Such
information is also important to help developing optimal risk screening
strategies and interventions to reduce women's future risk of diabetes
and CVD.
We only identiﬁed 3 studies that examined postpartum bio-
specimens, of which blood (serum/plasma) was collected at three days
postpartum by one study,45 and at twenty-two months following
birth by another.54 The 3rd study analyzed urine samples collected at
10–16 weeks postpartum.43 The serum/plasma metabolic prolife of
women who had experienced GDM compared to women without
GDM showed differences in levels of amino acids in two studies.45,54
Additional differences in phospholipids, acylcarnitines, fatty acids, and
diglycerides were also reported.54 No signiﬁcant biomarkers to distin-
guish GDMwomen and non-GDMwomen in the analysis of postpartum
urine.43
Reconciling the inconsistent results is challenging as all three studies
had substantial timing differences of sample collection, and type of
mass-spectrometer used. Likely, the type of specimen may explain the
inconsistent, given both studies examining blood found signiﬁcant
results, whereas analysis of urine was not.
2.4. Metabolomic proﬁles over time during the pregnancy (bio-specimen
collected longitudinally during pregnancy or postpartum)
Studies examining the changes in metabolites over time for
pregnant women with GDM as compared to women without GDM
during pregnancy and postpartum would provide the most valuable
data for understanding the etiology and pathogenesis of the GDM.
However, only 4 studies were identiﬁed that collected bio-specimens
longitudinally.38,39,43,45 Among 4 studies three studies only maden with gestational diabetes mellitus and their offspring: Review of
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Table 1
Summary of results by time of specimen collection from metabolomic studies investigating proﬁles of women with and without GDM.
Author,
country,
year
Study design &
methods
Sample
collection
time
Bio-specimens # of GDM/
non-GDM
Diagnostic
criteria
Metabolites in GDM group compared to control group
Increased Decreased
Bio-specimens collected priori to GDM diagnosis
Chen,
US, 2010
Nested case-
control (targeted
on FAs, GCMS)
16 weeks
GA
Serum
(fasting)
49/80
impaired
GCT/98
C & C FAs (myristic acid,
palmitic acid, palmitoleic,
and eicosapentaenoic acids)
None
Graça,
Portugal,
2010
Nested case-control
(untargeted, NMR)
14–25
weeks GA
Amniotic ﬂuid
(non-fasting)
27/82 N/A Glucose Amino acids (glutamate, glycine,
proline, serine, taurine), organic
acids (acetate, formate), creatinine,
glycerophosphocholine
Diaz, Portugal,
2011
Nested case-
control, untargeted
metabolite
proﬁling (NMR)
14–25
weeks GA
Plasma
(non-fasting)
14/20 N/A None Trimethylamine-N-oxide and betaine
Urine
(non-fasting)
29/25 Choline,
3-hydroxyisovalerate,
2-hydroxyisobutyrate,
N-methyl-2-pyridone-
5-carboxamide, N-methyl-
nicotinamide
None
Graça,
Portugal,
2012
Nested case-
control, untargeted
metabolite
proﬁling
(LCMS & NMR)
15–25
weeks GA
Amniotic ﬂuid
(non-fasting)
23/26 N/A Glucose Amino acids (glutamate)
Urine
(non-fasting)
20/21 Choline None
Sachse,
Norway,
2012
Nested case-
control, untargeted
metabolite
proﬁling (NMR)
8–20
weeks GA
Urine
(fasting)
79/530 WHO or
IADPSG
Citrate None
Diaz, Portugal,
2013
Nested case-
control, untargeted
metabolite
proﬁling (NMR)
14–26
weeks GA
Urine
(non-fasting)
42/84 N/A Choline, glucose, N-methyl-
nicotinamide, xylose
4-Hydroxyphenylacetat, hippurate
De Seymour,
New
Zealand,
2014
Nested case-
control
(untargeted,
GCMS)
20 weeks
GA
Serum (N/A) 22/26 N/A Itaconic acid, cis-aconitate
acid
None
Bentley-Lewis,
US, 2015
Nested case-control
(untargeted, LCMS)
b12 weeks
GA
Serum
(fasting)
96/96 C & C Anthranilic acid, allantoin,
amino acids (alanine,
glutamate, and serine)
Creatinine
Law, China,
2017
Nested case-control
(untargeted, LCMS)
11–14
weeks GA
Plasma
(fasting)
27/34 IADPSG Sesaminol 2-O-triglucoside,
tricin 7-neohesperidoside
Phospholipids (unsaturated and/
or chemically modiﬁed), (2E)-14-
hydroxytetradec-2-enoic acid or
its isomer,
(2E,13R)-13-hydroxytetradec-
2-enoic acid, 2,15-dihydroxy-
pentadecanoic acid (or its isomers),
(7R,8S,9Z,12Z,15Z)-7,8-dihydroxy-9,12,
15-octadecatrienoic acid
Bio-specimens collected after or simultaneous to GDM diagnosis
Chen US,
2010
Nested case-
control (targeted
on FAs, GCMS)
30 weeks
GA
Serum
(fasting)
49/80
impaired
GCT/98
C & C FAs (palmitic acid,
palmitoleic
acid, oleic acid, linoleic acid
(18:2), linolenic acid (18:3),
arachidonic acid (20:4),
eicosapentaenoic acid,
and docosahexaenoic acids)
None
Sachse,
Norway,
2012
Nested case-control
(untargeted, NMR)
26–30
weeks GA
Urine
(fasting)
79/530 WHO or
IADPSG
Citrate None
Dudzik,
Poland,
2014
Case-control
(untargeted,
GCMS/LCMS/CEMS)
22–28
weeks GA
Plasma
(fasting)
20/20 WHO-
1998
Phosphatidylethanolamines
(38:6, 36:5),
Phosphatidylcholines
(38:1, 40:3), acetylcarnitine,
FAs (linoleic acid), glycerol,
3-hydroxybutyrate,
2-hydroxybutyrate,
and fumaric acid
Glycerophospholipids
(e.g. lysophosphatidylethanolamines
(LPE with 16:0, 18:0, 18:2, 20:0,
20:1, 20:2, 22:4 and 22:6 chains);
lysophosphatidylcholines (LPC with
16:0; 18:0, 18:1, 18:2, 18:3, 20:3, 20:4,
20:5 acyl chains);
lysophosphatidylinositol
LPI 20:4); lysophosphatidylserine
(LPS with 20:0); lysophosphatidic acid
(LPA with 18:2); lipoxin C4), bile acids
(trihydroxy-cholestanoyl taurine;
taurolithocholic acid glucuronide),
araquidonate and docosahexaenoic
acid methyl esters,
glycerophosphocholine,
creatinine, pyruvic acid, amino acids
4 Q. Chen et al. / Journal of Diabetes and Its Complications xxx (2018) xxx–xxx
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Table 1 (continued)
Author,
country,
year
Study design &
methods
Sample
collection
time
Bio-specimens # of GDM/
non-GDM
Diagnostic
criteria
Metabolites in GDM group compared to control group
Increased Decreased
(L-tryptophan, glycine,
L-glutamic acid), FAs
(lauric acid)
Urine
(fasting)
Amino acids (histidine,
glutamine,
phenylalanine, tryptophan
and cystine)
Carnitine
Prentice,
US, 2014
Case-control
(untargeted
GCMS/LCMS)
24–28
weeks GA
Plasma
(fasting)
24/24 NIH FAs (primary
polyunsaturated
fatty acids: the largest
increased is
3-carboxy-4-methyl-
5-propyl-2-furanpropanoic
acid (CMPF))
None
Scholtens,
multiple
countries,
2014
Case-control
(targeted on
amino acids
and untargeted,
MS/GCMS)
24–32
weeks GA
Serum
(fasting)
67/50
(b10th
percentile
end of FPG)
from HAPO
study
IADPSG Amino acids (alanine,
proline, and branched-
chain amino acids),
carbohydrates (primary
glucose), lipids (palmitic
acid, lauric acid,
heptadecanoic
acid, β-tocopherol), ketone
bodies (β-hydroxybutyric
acid,
acetoacetic acid), and
organic
acids (pyruvic acid,
α-ketoglutaric acid,
2-hydroxybutyric acid,
isocitric acid, and
creatinine)
1,5-Anhydroglucitol, mannitol
and other hexitols, β-sitosterol
Lorenzo,
Poland,
2015
Case-control
(targeted on
amino acids,
GCMS)
22–28
weeks GA
Urine
(fasting)
20/20 WHO-1998 D-Phenylalanine None
Hajduk,
Poland,
2015
Case-control
(targeted on
amino acids,
LCMS)
24–28
weeks GA
Plasma 18/13 Polish
Gynecological
Society
Standards
L-Citrulline L-Asparagine, L-valine,
and L-ornithine
He, China
2016
Case-control
(untargeted,
GCMS)
24–28
weeks GA
Hair 47/47 IADPSG Adipic acid None
Lehmann,
Germany,
2015
Case-control
(targeted,
GCMS/LCMS)
24–27
weeks GA
Plasma
(fasting)
9/15 IADPSG Acetylcarnitine, amino
acids (leucine),
FAs (oleate)
Glycerophospholipids,
amino acid (glycine),
lysophosphatidylcholines,
FAs (C22:4, C22:5)
Gao, China,
2016
Case-control
(targeted on
bile acid, LCMS)
~28 weeks
GA
Serum
(fasting)
38/27 IADPSG Bile acids (1 trihydroxy
unconjugated (β-muricholic
acid), 2 dihydroxy
conjugated
(glycohyodeoxycholic acid
and
taurohyodeoxycholic acid)
and 5 sulfated (dehydro-1S,
mono-2S+ mono-3S,
mono-4S, and mono-5S))
None
Liu, China,
2016
Nested case-
control
(untargeted,
LCMS)
28–36
weeks GA
Serum
(fasting)
12/10 IADPSG 1-Methyladenosine,
homovanillic acid,
trans-3-octenedioic
acid, glucosamine,
lysophosphatidylcholines
(LPC with 16:1, 20:2),
3-methylthiopropionic
acid, L-lactic acid, amino
acid (L-tyrosine),
L-2-hydroxyglutaric acid,
and phosphorylcholine
Gluconolactone, serinyl-glycine,
lysophosphatidylcholines
(LPC with 20:4), 3-methylhistidine,
2-oxo-4-methylthiobutanoic acid,
sphingomyelin (SM with d18:0/18:0),
indoleacetaldehyde,
phosphatidylethanola
mines (PE with 14:1/20:0),
3-oxooctadecanoic acid, amino acid
(glycine), pyridoxal, FAs (capric acid,
stearic acid), 3-methylhistidine,
and arabinonic acid
Law, China,
2017
Nested case-
control
(untargeted,
LCMS)
23–27 &
29–33
weeks GA
Plasma
(fasting)
27/34 IADPSG Prostanoic acid, sesaminol
2-O-triglucoside, tricin
7-neohesperidoside, and
dihydro-12-oxo-15-
phytoenoic acid
Phospholipids (unsaturated and/or
chemically modiﬁed), (2E)-14-
hydroxytetradec-2-enoic acid or
its isomer, (2E,13R)-
13-hydroxytetradec-
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Table 1 (continued)
Author,
country,
year
Study design &
methods
Sample
collection
time
Bio-specimens # of GDM/
non-GDM
Diagnostic
criteria
Metabolites in GDM group compared to control group
Increased Decreased
2-enoic acid, 2,15-dihydroxy-
pentadecanoic acid (or its isomers),
(7R,8S,9Z,12Z,15Z)-7,8-dihydroxy-
9,12,15-octadecatrienoic acid, and
11α,20,26-trihydroxyecdysone
Bio-specimens collected postpartum
Sachse,
Norway,
2012
Nested case-
control
(untargeted,
NMR)
10–16
weeks PP
Urine
(fasting)
79/530 WHO None None
Anderson,
UK, 2014
Case-
control
(untargeted,
LCMS)
22 months
PP
Serum
(fasting)
18/39
(hyperglycemia
but not
GDM)/43
WHO Phospholipids (e.g.
lysophosphatidylcholine
(LPC with 20:1),
lysophosphatidylglycine
(LPG with 18:1),
phosphatidylserine
(PS with 30;7)
acylcarnitines,
FAs, amino acids, bile
acids, and diglycerides
Phospholipids (e.g.
lysophosphatidylcholines
(LPC (10:1; 16:2)),
lysophosphatidylethanolamine
(LPE with 18:1), phosphatidylinositol
(PI with 36;3), phosphatidylcholines
(PC with 34:0; 38:0)
Liu, China,
2016
Nested
case-
control
(untargeted,
LCMS)
Within 3
days PP
Serum
(fasting)
12/10 IADPSG L-Carnitine and creatine Amino acid (L-lysine), vitamin A,
ribothymidine, corticosterone,
lysophosphatidylethanolamine
(PE with 22:6/0:0),
17-hydroxyprogesterone,
and 1, 4-beta-D-glucan
Note for all abbreviations: GCT, glucose challenge test;WHO,WorldHealthOrganization; IADPSG, International Association ofDiabetes andPregnancy StudyGroups; GA, gestation age; PP,
postpartum; GCMS, gas chromatography/mass spectrometry; LCMS, liquid chromatography/mass spectrometry; CEMS, capillary electrophoresis/mass spectrometry; NMR, nuclear mag-
netic resonance; C&C, Carpenter-Coustan criteria; FA, fatty acids; FPG fasting plasma glucose; HAPO Study the Hyperglycemia and Adverse Pregnancy Outcome Study.
6 Q. Chen et al. / Journal of Diabetes and Its Complications xxx (2018) xxx–xxxcross-sectional comparisons (results have been summarized in previous
sections and can be found in Table 1).38,43,45 Cross-sectional compari-
sons provide insight into differences between GDM and non-GDM
women at different time points during pregnancy, but do not allow for
comparisons of the trend in metabolic proﬁle change throughout
gestation.
Only one recent study comparing women with GDM to women
without GDM identiﬁed changes in the metabolic proﬁle over time.39
In this study, plasma samples were collected during the ﬁrst, second,
and third trimesters. The primary ﬁnding was that polyunsaturated
(or chemically modiﬁed) phospholipids had an increasing trend in all
women from the ﬁrst to third trimester, but women with GDM had
consistently lower levels as compared to the women without GDM
– with the smallest difference observed at 23–27 weeks gestation.39
Signiﬁcantly higher levels of sesaminol 2-O-triglucoside and tricin
7-neohesperidoside, and lower levels of (2E)-14-hydroxytetradec-
2-enoic acid (or its isomer) and (7R,8S,9Z,12Z,15Z)-7,8-dihydroxy-
9,12,15-octadecatrienoic acid were also found in women with
GDM throughout the pregnancy. In late pregnancy, signiﬁcant
differences of dihydro-12-oxo-15-phytoenoic acid, and 11α,20,26-
trihydroxyecdysone, and prostanoic acid levels between GDM and
non-GDM women were found.392.5. Metabolomic proﬁles of offspring of women who had GDM
Studies comparing themetabolic proﬁle of offspring whose mothers
had GDM to mothers who did not are extremely limited (Table 2). Two
studies were identiﬁed in this area: one study examined newborns'
meconium metabolome55 and reported changes in lipid, amino acid,
and purine metabolism for babies born to mothers with GDM; the
other study examined cord blood56 and reported increased levels of
amino acids, pyruvate, histidine, alanine, methionine, arginine, lysine,
hypoxanthine, lipoprotein and lipids, as well as lower levels of glucose.
However, whether these metabolic differnences are associatedwith thePlease cite this article as: Chen Q, et al. Metabolomic proﬁling of wome
metabolomics studies. (2018), https://doi.org/10.1016/j.jdiacomp.2018.01development of obesity and diabetes in offspring of mothers who had
GDM remains uncertain.
3. Summary and the future of research
Currently, there are a lack of tools with high sensitivity and high
speciﬁcity capable of identifying women in early pregnancy who are
at risk of developing GDM. As a result, both mothers and fetus are not
treated until late in the second trimester when GDM is diagnosed
based on current criteria. The uncontrolled metabolic changes during
early pregnancy in women who later develop GDM are likely to have
adverse consequences for fetal development, and for the long-term
health for the offspring. Although high-throughput metabolomics is
thought to aid our understanding of the etiology and pathogeneses of
GDM, the current review outlines the complexity of drawing conclu-
sions from current metabolomics research in GDM.
Many of the studies reviewed found signiﬁcant differences in amino
acids & related metabolites, fatty acids & related metabolites, phospho-
lipids, and bile acids between women with GDM and without GDM.
However, results are highly inconsistencies regarding the direction
and signiﬁcance of speciﬁc metabolites across studies. Findings from
one study have not been replicated by another study. There aremultiple
possible explanations for such highly inconsistent results. First, studies
in this area employed different bio-specimens. Of the studies included
in this review, ﬁfteen analyzed blood (plasma/serum), seven analyzed
urine, two analyzed amniotic ﬂuids, and one analyzed hair samples.
Second, whether participants were fasting at time of biospecimen col-
lectionwas inconsistent (Table 1). Third, the instruments and technolo-
gies used to analyze biospecimens varied across the studies. Fourth,
GDM diagnosis criteria are different among studies. Lastly, age and eth-
nic/racial background of the study population are likely to contribute to
the inconsistent ﬁndings.
Despite the inconsistent results from the literature, identiﬁed
biomarkers from the reviewed metabolomics research are involved
in speciﬁc metabolite groups and several important pathways,n with gestational diabetes mellitus and their offspring: Review of
.007
Table 2
Summary of results from metabolomic studies investigating proﬁles of offspring born to women with and without GDM.
Author,
country, year
Study design # of GDM/
non-GDM
Offspring
age
Diagnostic
criteria
Bio-specimens Metabolites in GDM group compared to control group
Increased Decreased
Dani, Italy,
2014
Case-control
(untargeted,
NMR)
30/40 Newborn IADPSG Cord blood
serum
Pyruvate, histidine, alanine,
valine, methionine, arginine,
lysine, hypoxanthine,
lipoprotein and lipid
Glucose
Peng, China,
2015
Case-control
(untargeted,
LCMS)
142/197 Newborn WHO Meconium Amino acids derivative
(argininosuccinic acid,
tetrahydrodipicolinate);
purine alkaloid metabolites
(methyladenosine, methylxanthine,
dimethyluric acid); bile acid
derivative (taurodeoxycholic acid);
DHAP (8:0); polyphenol host
metabolites (methylepicatechin)
Amino acids derivative
(hydroxyindoleacetylglycine);
purine alkaloid metabolites
(methylguanosine; uric acid);
bile acid derivative
(glycocholic acid); fatty
acid derivative
(oxotrihydroxyleukotrinen
B4); polyphenol host
metabolites (vanilloylglycine)
Urine Uric acid, uridine Estrone
Note for all abbreviations:WHO,WorldHealth Organization; IADPSG, International Association of Diabetes and Pregnancy Study Groups; GCMS, gas chromatography/mass spectrometry;
LCMS, liquid chromatography/mass spectrometry; CEMS, capillary electrophoresis/mass spectrometry; NMR, nuclearmagnetic resonance; C&C, Carpenter-Coustan criteria; FA, fatty acids.
7Q. Chen et al. / Journal of Diabetes and Its Complications xxx (2018) xxx–xxxincluding amino acid metabolism, steroid hormone biosynthesis,
glycerophospholipid metabolism, and fatty acid metabolism. For
example, amino acids (particularly branched chain amino acids,
BCAAs) have been consistently associated with insulin resistance
and pancreatic β-cell dysfunction. Since 1969, a prominent BCAA sig-
nature of insulin resistance has been observed in normoglycemic
adults, obese, prediabetes and diabetes population.32,57,58 Several
important metabolic pathways underlying these associations have
been proposed. Recent studies found that elevated circulating BCAA
might lead to excess trans-endothelial fatty acid transport into skel-
etal muscle, promote lipid accumulation and blunt insulin signaling
via secretion of 3-hydroxyisobutyrate.59 BCAAs play a key role in
activating the pathway of the mammalian target of rapamycin
complex-1 (mTORC1) involved in T2D, and the pathways of other
metabolic disorders pathways.60 This activation results in inducing
a set of anabolic responses, including protein synthesis, cell growth,
lipid synthesis, and, most importantly, insulin resistance.61
Although there are commonalities between the pathogenesis of T2D
and GDM, and these disorders may share the previously mentioned
metabolic pathway, the associations reported between amino acids
and GDM in the current review were contrary or insigniﬁcant. Two
studies observed that BCAAs were elevated in GDM women at 28
weeks gestation and 22 months postpartum,47,54 one study reported
decreased L-valine in GDM women at 24–28 weeks gestation,46 and
numerous studies found no signiﬁcant differences.36,37,42,43,52,53 The
inconsistence ﬁndings in GDM are likely caused by the differences in
genetic background, dietary intakes, and samples collected at different
time points and environmental impacts.
The studies reviewed reported a series of lipid levels to be different be-
tween GDM and non-GDMwomen. Brieﬂy, most studies examining pre-
or post-diagnosis GDM cases, found fatty acids to be elevated,38,48–50,54
while glycerophospholipids to be decreased44,45,48,49,54 compared with
healthy pregnancy controls. The mechanism of elevated maternal
circulating fatty acids and GDMmay be explained by increased insulin
resistance and impaired β-cell function via accumulation of toxic
intracellular lipid derivatives, oxidative stress, inﬂammation, and mito-
chondrial dysfunction.38,50,62,63 The observations of decreased circulating
glycerophospholipids (most prominent in lysoglycerophospholipids)
during pregnancy39,45,48 and postpartum,45,54 are in line with ﬁndings
from studies of T2D.32 The alignment with studies of T2D suggests that
the pathogenesis of GDM might be related to β-cell dysfunction,48
alteration in enzymatic activities (e.g. lower levels of cytosolic
calcium-dependent phospholipase-A2 isoform),64 and an unbalanced
pro-inﬂammatory versus anti-inﬂammatory ratio.48Please cite this article as: Chen Q, et al. Metabolomic proﬁling of wome
metabolomics studies. (2018), https://doi.org/10.1016/j.jdiacomp.2018.01It is worthy to note that the marked increase of glucose in amni-
otic ﬂuid sample42,44 and choline in urine samples40–42 during the
ﬁrst and second trimester are possibly an early sign of hyperglyce-
mia. Future studies are needed to conﬁrm such results in different
populations.
Huynh et al published the ﬁrst high quality review of metabolo-
mics studies of GDM in 2014.65 However, the current review
includes more recent studies published after February 2014. In addi-
tion, we reviewed studies by the timing of bio-specimen collection
(e.g. before or after diagnosis of GDM, or postpartum), and reported
studies that investigated the metabolic proﬁle of offspring of
mothers who had GDM in the index pregnancy. This review provided
updates on the application of metabolomics in GDM epidemiological
and clinical studies.
Several research gaps were identiﬁed by this review. Most studies
were small in sample size, with the largest study including only 79
GDMcases and 530 non-GDMcontrols.43 Few studies included informa-
tion on dietary intake, which would have a signiﬁcant inﬂuence on an
individual's metabolites levels in blood, urine, or other tissue, particu-
larly for amino acids and fatty acids and their related metabolites.
Studies investigating the metabolic proﬁles of offspring born to GDM
mothers are scarce, with only two studies identiﬁed in this review and
only including newborns. Finally, the statistical methods used to com-
pare metabolic proﬁles and identify signiﬁcant differences between
groups were highly inconsistent. Developing new computational tools
to facilitate the analysis and interpretation of complex metabolomics
data sets is highly needed.
From an epidemiological perspective, the use of metabolomics as
a novel strategy for identifying GDM and improving maternal and
infant outcomes requires reﬁnement. The clinical implication for
utilizing metabolomics to inform diagnosis, management, and prog-
nosis of GDM and related complications is plausible, but as of yet
there remains a need for further improvement in consensus of meth-
odology before any informative conclusions can be drawn. In sum-
mary, future studies should investigate: 1) the appropriate bio-
specimens that should be collected, 2) the optimal timing for
collecting bio-specimens, 3) the adequate sample size, and 4) appro-
priate statistical approaches. Taken together, the available data
is insufﬁcient to draw any solid conclusions. More research in meta-
bolomics with large sample sizes, rigorous data collection and appro-
priate statistical methods, and across various populations are
warranted to determine if metabolomics will result in new indica-
tors for the diagnosis, management, and prognosis of GDM and
related complications.n with gestational diabetes mellitus and their offspring: Review of
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1. Population Women with GDM during
pregnancy (gestational
diabetes mellitus or GDM)
(“diabetes, gestational”[MeSH Terms] OR (“diabetes”[All Fields] AND “gestational”[All Fields]) OR “gestational diabetes”[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND “mellitus”[All Fields]) OR “gestational diabetes
mellitus”[All Fields]) OR GDM[All Fields]
2. Exposure Metabolomics (metabolomics
or metabolome)
(‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH Terms] OR ‘metabolome’[All Fields])
3. Outcome Type 2 Diabetes at follow-up “diabetes mellitus”[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘diabetes mellitus’[All Fields] OR
‘diabetes’[All Fields] OR “type 2 diabetes”[All Fields] OR “metabolic diseases”[MeSH Terms] OR ‘insulin resistance’[All Fields]
OR “insulin sensitivity”[All ﬁelds] OR “metabolic syndrome x”[MeSH Terms] OR ‘metabolic syndrome’[All Fields] OR
‘HOMA-IR’[All Fields] OR “HOMA- beta”[All Fields] OR ‘impaired glucose’[All Fields]
4. Outcome Children Obesity (obese OR
overweight OR body mass index
OR BMI OR body weight OR
adiposity)
(((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR “obese”[All Fields]) OR (‘overweight’[MeSH Terms] OR
‘overweight’[All Fields])) OR (“body mass index”[MeSH Terms] OR (“body”[All Fields] AND “mass”[All Fields] AND
“index”[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body weight’[MeSH Terms] OR (‘body’[All
Fields] AND “weight”[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH Terms] OR ‘adiposity’[All Fields])
5. Study type Cohort Study (cohort study OR
longitudinal studies OR
prospective study OR hazard
ratio)
(((“cohort studies”[MeSH Terms] OR (“cohort”[All Fields] AND “studies”[All Fields]) OR ‘cohort studies’[All Fields] OR
(‘cohort’[All Fields] AND “study”[All Fields]) OR “cohort study”[All Fields]) OR (“longitudinal studies”[MeSH Terms] OR
(“longitudinal”[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR (“prospective studies”[MeSH
Terms] OR (“prospective”[All Fields] AND ‘studies’[All Fields]) OR ‘prospective studies’[All Fields] OR (‘prospective’[All
Fields] AND ‘study’[All Fields]) OR “prospective study”[All Fields])) OR (hazard[All Fields] AND (“Ratio (Oxf)”[Journal] OR
“ratio”[All Fields]))
6. Study
subjects
Human Study
1 + 2 + 4
+ 6 + 7
Human cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND ((‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH
Terms] OR ‘metabolome’[All Fields]))) AND (‘diabetes mellitus’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘mellitus’[All
Fields]) OR ‘diabetes mellitus’[All Fields] OR ‘diabetes’[All Fields] OR ‘type 2 diabetes’[All Fields] OR ‘metabolic
diseases’[MeSH Terms] OR ‘insulin resistance’[All Fields] OR ‘insulin sensitivity’[All ﬁelds] OR ‘metabolic syndrome x’[MeSH
Terms] OR ‘metabolic syndrome’[All Fields] OR ‘HOMA-IR’[All Fields] OR “HOMA- beta”[All Fields] OR ‘impaired glucose’[All
Fields])) AND ((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND ‘studies’[All Fields]) OR ‘cohort studies’[All
Fields] OR (‘cohort’[All Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All Fields]) OR (‘longitudinal studies’[MeSH Terms]
OR (‘longitudinal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR (‘prospective studies’[MeSH
Terms] OR (‘prospective’[All Fields] AND ‘studies’[All Fields]) OR ‘prospective studies’[All Fields] OR (‘prospective’[All Fields]
AND ‘study’[All Fields]) OR ‘prospective study’[All Fields])) OR (hazard[All Fields] AND (‘Ratio (Oxf)’[Journal] OR ‘ratio’[All
Fields]))) AND “humans”[MeSH Terms]
1 + 2 + 4
+ 6
Cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (“gastrointestinal microbiome”[MeSH Terms] OR (“gastrointestinal”[All Fields] AND
“microbiome”[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND “microbiota”[All
Fields]) OR “gastrointestinal microbiota”[All Fields])) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR
‘obese’[All Fields]) OR (‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR
(‘body’[All Fields] AND ‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR
(‘body weight’[MeSH Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR
(‘adiposity’[MeSH Terms] OR ‘adiposity’[All Fields]))) AND ((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND
‘studies’[All Fields]) OR ‘cohort studies’[All Fields] OR (‘cohort’[All Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All
Fields]) OR (‘longitudinal studies’[MeSH Terms] OR (‘longitudinal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal
studies’[All Fields])) OR (‘prospective studies’[MeSH Terms] OR (‘prospective’[All Fields] AND ‘studies’[All Fields]) OR
‘prospective studies’[All Fields] OR (‘prospective’[All Fields] AND ‘study’[All Fields]) OR ‘prospective study’[All Fields])) OR
(hazard[All Fields] AND (‘Ratio (Oxf)’[Journal] OR ‘ratio’[All Fields])))
1 + 3 + 4
+ 6 + 7
Human cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All
Fields]) OR (‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All
Fields] AND ‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body
weight’[MeSH Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH
Terms] OR ‘adiposity’[All Fields]))) AND ((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND ‘studies’[All Fields])
OR ‘cohort studies’[All Fields] OR (‘cohort’[All Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All Fields]) OR (‘longitudinal
studies’[MeSH Terms] OR (‘longitudinal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR
(‘prospective studies’[MeSH Terms] OR (‘prospective’[All Fields] AND ‘studies’[All Fields]) OR ‘prospective studies’[All
Fields] OR (‘prospective’[All Fields] AND ‘study’[All Fields]) OR ‘prospective study’[All Fields])) OR (hazard[All Fields] AND
(‘Ratio (Oxf)’[Journal] OR ‘ratio’[All Fields]))) AND ‘humans’[MeSH Terms]
1 + 3 + 4
+ 6
Cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND (‘diabetes mellitus’[MeSH Terms] OR (‘diabetes’[All Fields] AND
‘mellitus’[All Fields]) OR ‘diabetes mellitus’[All Fields] OR ‘diabetes’[All Fields] OR ‘type 2 diabetes’[All Fields] OR ‘metabolic
diseases’[MeSH Terms] OR ‘insulin resistance’[All Fields] OR ‘insulin sensitivity’[All ﬁelds] OR ‘metabolic syndrome x’[MeSH Terms]
OR ‘metabolic syndrome’[All Fields] OR ‘HOMA-IR’[All Fields] OR “HOMA- beta”[All Fields] OR ‘impaired glucose’[All Fields])) AND
((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND ‘studies’[All Fields]) OR ‘cohort studies’[All Fields] OR (‘cohort’[All
Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All Fields]) OR (‘longitudinal studies’[MeSH Terms] OR (‘longitudinal’[All Fields]
AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR (‘prospective studies’[MeSH Terms] OR (‘prospective’[All Fields]
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AND ‘studies’[All Fields]) OR ‘prospective studies’[All Fields] OR (‘prospective’[All Fields] AND ‘study’[All Fields]) OR ‘prospective
study’[All Fields])) OR (hazard[All Fields] AND (‘Ratio (Oxf)’[Journal] OR ‘ratio’[All Fields])))
1 + 2 + 5
+ 6+ 7
Human cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND ((‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH
Terms] OR ‘metabolome’[All Fields]))) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All Fields]) OR
(‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All Fields] AND
‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body weight’[MeSH
Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH Terms] OR
‘adiposity’[All Fields]))) AND ((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND ‘studies’[All Fields]) OR ‘cohort
studies’[All Fields] OR (‘cohort’[All Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All Fields]) OR (‘longitudinal
studies’[MeSH Terms] OR (‘longitudinal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR
(‘prospective studies’[MeSH Terms] OR (‘prospective’[All Fields] AND ‘studies’[All Fields]) OR ‘prospective studies’[All
Fields] OR (‘prospective’[All Fields] AND ‘study’[All Fields]) OR ‘prospective study’[All Fields])) OR (hazard[All Fields] AND
(‘Ratio (Oxf)’[Journal] OR ‘ratio’[All Fields]))) AND ‘humans’[MeSH Terms]
1 + 2 + 5
+ 6
Cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND ((‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH
Terms] OR ‘metabolome’[All Fields]))) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All Fields]) OR
(‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All Fields] AND
‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body weight’[MeSH
Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH Terms] OR
‘adiposity’[All Fields]))) AND ((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND ‘studies’[All Fields]) OR ‘cohort
studies’[All Fields] OR (‘cohort’[All Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All Fields]) OR (‘longitudinal
studies’[MeSH Terms] OR (‘longitudinal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR
(‘prospective studies’[MeSH Terms] OR (‘prospective’[All Fields] AND ‘studies’[All Fields]) OR ‘prospective studies’[All
Fields] OR (‘prospective’[All Fields] AND ‘study’[All Fields]) OR ‘prospective study’[All Fields])) OR (hazard[All Fields] AND
(‘Ratio (Oxf)’[Journal] OR ‘ratio’[All Fields])))
1 + 3 + 5
+ 6+ 7
Human cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All
Fields]) OR (‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All
Fields] AND ‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body
weight’[MeSH Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH
Terms] OR ‘adiposity’[All Fields]))) AND ((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND ‘studies’[All Fields])
OR ‘cohort studies’[All Fields] OR (‘cohort’[All Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All Fields]) OR (‘longitudinal
studies’[MeSH Terms] OR (‘longitudinal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR
(‘prospective studies’[MeSH Terms] OR (‘prospective’[All Fields] AND ‘studies’[All Fields]) OR ‘prospective studies’[All
Fields] OR (‘prospective’[All Fields] AND ‘study’[All Fields]) OR ‘prospective study’[All Fields])) OR (hazard[All Fields] AND
(‘Ratio (Oxf)’[Journal] OR ‘ratio’[All Fields]))) AND ‘humans’[MeSH Terms]
1 + 3 + 5
+ 6
Cohort ((((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All
Fields]) OR (‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All
Fields] AND ‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body
weight’[MeSH Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH
Terms] OR ‘adiposity’[All Fields]))) AND ((((‘cohort studies’[MeSH Terms] OR (‘cohort’[All Fields] AND ‘studies’[All Fields])
OR ‘cohort studies’[All Fields] OR (‘cohort’[All Fields] AND ‘study’[All Fields]) OR ‘cohort study’[All Fields]) OR (‘longitudinal
studies’[MeSH Terms] OR (‘longitudinal’[All Fields] AND ‘studies’[All Fields]) OR ‘longitudinal studies’[All Fields])) OR
(‘prospective studies’[MeSH Terms] OR (‘prospective’[All Fields] AND ‘studies’[All Fields]) OR ‘prospective studies’[All
Fields] OR (‘prospective’[All Fields] AND ‘study’[All Fields]) OR ‘prospective study’[All Fields])) OR (hazard[All Fields] AND
(‘Ratio (Oxf)’[Journal] OR ‘ratio’[All Fields])))
1 + 2 + 4 All study (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND ((‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH
Terms] OR ‘metabolome’[All Fields]))) AND (‘diabetes mellitus’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘mellitus’[All
Fields]) OR ‘diabetes mellitus’[All Fields] OR ‘diabetes’[All Fields] OR ‘type 2 diabetes’[All Fields] OR ‘metabolic
diseases’[MeSH Terms] OR ‘insulin resistance’[All Fields] OR ‘insulin sensitivity’[All ﬁelds] OR ‘metabolic syndrome x’[MeSH
Terms] OR ‘metabolic syndrome’[All Fields] OR ‘HOMA-IR’[All Fields] OR “HOMA- beta”[All Fields] OR ‘impaired glucose’[All
Fields])
1 + 2 + 4
+ 7
Human (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND ((‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH
Terms] OR ‘metabolome’[All Fields]))) AND (‘diabetes mellitus’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘mellitus’[All
Fields]) OR ‘diabetes mellitus’[All Fields] OR ‘diabetes’[All Fields] OR ‘type 2 diabetes’[All Fields] OR ‘metabolic
diseases’[MeSH Terms] OR ‘insulin resistance’[All Fields] OR ‘insulin sensitivity’[All ﬁelds] OR ‘metabolic syndrome x’[MeSH
Terms] OR ‘metabolic syndrome’[All Fields] OR ‘HOMA-IR’[All Fields] OR “HOMA- beta”[All Fields] OR ‘impaired glucose’[All
Fields]) AND ‘humans’[MeSH Terms]
1 + 3 + 4 All study (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND (‘diabetes mellitus’[MeSH Terms] OR (‘diabetes’[All Fields] AND
‘mellitus’[All Fields]) OR ‘diabetes mellitus’[All Fields] OR ‘diabetes’[All Fields] OR ‘type 2 diabetes’[All Fields] OR ‘metabolic
diseases’[MeSH Terms] OR ‘insulin resistance’[All Fields] OR ‘insulin sensitivity’[All ﬁelds] OR ‘metabolic syndrome x’[MeSH
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Terms] OR ‘metabolic syndrome’[All Fields] OR ‘HOMA-IR’[All Fields] OR “HOMA- beta”[All Fields] OR ‘impaired glucose’[All
Fields])
1 + 3 + 4
+ 7
Human (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND (‘diabetes mellitus’[MeSH Terms] OR (‘diabetes’[All Fields] AND
‘mellitus’[All Fields]) OR ‘diabetes mellitus’[All Fields] OR ‘diabetes’[All Fields] OR ‘type 2 diabetes’[All Fields] OR ‘metabolic
diseases’[MeSH Terms] OR ‘insulin resistance’[All Fields] OR ‘insulin sensitivity’[All ﬁelds] OR ‘metabolic syndrome x’[MeSH
Terms] OR ‘metabolic syndrome’[All Fields] OR ‘HOMA-IR’[All Fields] OR “HOMA- beta”[All Fields] OR ‘impaired glucose’[All
Fields]) AND ‘humans’[MeSH Terms]
1 + 2 + 5 All study (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND ((‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH
Terms] OR ‘metabolome’[All Fields]))) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All Fields]) OR
(‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All Fields] AND
‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body weight’[MeSH
Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH Terms] OR
‘adiposity’[All Fields]))
1 + 2 + 5
+ 7
Human (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND ((‘metabolomics’[MeSH Terms] OR ‘metabolomics’[All Fields]) OR (‘metabolome’[MeSH
Terms] OR ‘metabolome’[All Fields]))) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All Fields]) OR
(‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All Fields] AND
‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body weight’[MeSH
Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH Terms] OR
‘adiposity’[All Fields])) AND ‘humans’[MeSH Terms]
1 + 3 + 5 All study (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All
Fields]) OR (‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All
Fields] AND ‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body
weight’[MeSH Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH
Terms] OR ‘adiposity’[All Fields]))
1 + 3 + 5
+ 7
Human (((‘diabetes, gestational’[MeSH Terms] OR (‘diabetes’[All Fields] AND ‘gestational’[All Fields]) OR ‘gestational diabetes’[All
Fields] OR (‘gestational’[All Fields] AND ‘diabetes’[All Fields] AND ‘mellitus’[All Fields]) OR ‘gestational diabetes mellitus’[All
Fields]) OR GDM[All Fields]) AND (‘gastrointestinal microbiome’[MeSH Terms] OR (‘gastrointestinal’[All Fields] AND
‘microbiome’[All Fields]) OR ‘gastrointestinal microbiome’[All Fields] OR (‘gastrointestinal’[All Fields] AND ‘microbiota’[All
Fields]) OR ‘gastrointestinal microbiota’[All Fields])) AND ((((((‘obesity’[MeSH Terms] OR ‘obesity’[All Fields] OR ‘obese’[All
Fields]) OR (‘overweight’[MeSH Terms] OR ‘overweight’[All Fields])) OR (‘body mass index’[MeSH Terms] OR (‘body’[All
Fields] AND ‘mass’[All Fields] AND ‘index’[All Fields]) OR ‘body mass index’[All Fields])) OR BMI[All Fields]) OR (‘body
weight’[MeSH Terms] OR (‘body’[All Fields] AND ‘weight’[All Fields]) OR ‘body weight’[All Fields])) OR (‘adiposity’[MeSH
Terms] OR ‘adiposity’[All Fields])) AND ‘humans’[MeSH Terms]
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